Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axcella Health Inc. stock logo
AXLA
Axcella Health
$0.40
$0.84
$0.34
$41.25
$1.18M0.46267,009 shs6,782 shs
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$5.85
-1.5%
$5.30
$3.79
$14.60
$293.10M-0.921.45 million shs824,902 shs
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
$0.31
+2.0%
$0.31
$0.22
$4.33
$18.13M1.591.38 million shs261,997 shs
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
$2.30
-12.5%
$1.60
$1.20
$20.00
$3.23M-0.24606,507 shs168,173 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axcella Health Inc. stock logo
AXLA
Axcella Health
0.00%0.00%0.00%0.00%0.00%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
+6.07%+8.59%+19.52%-30.93%-30.53%
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
-0.98%-4.54%-15.03%-41.27%-92.10%
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
+11.44%+52.02%+59.39%+25.24%-86.27%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Axcella Health Inc. stock logo
AXLA
Axcella Health
N/AN/AN/AN/AN/AN/AN/AN/A
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
1.9321 of 5 stars
3.51.00.00.02.31.70.6
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
2.6583 of 5 stars
4.22.00.00.01.91.70.6
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
2.7342 of 5 stars
3.55.00.00.02.51.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axcella Health Inc. stock logo
AXLA
Axcella Health
0.00
N/AN/AN/A
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
3.00
Buy$21.00258.97% Upside
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
2.30
Hold$3.391,006.08% Upside
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
3.00
Buy$10.00334.78% Upside

Current Analyst Ratings Breakdown

Latest CADL, ELEV, AXLA, and EVAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/11/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
4/2/2025
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
3/24/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$5.00 ➝ $1.00
3/21/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform
3/21/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$9.00 ➝ $1.00
3/21/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
3/21/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$10.00 ➝ $0.70
3/21/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $1.00
3/20/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
3/20/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
3/14/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axcella Health Inc. stock logo
AXLA
Axcella Health
N/AN/AN/AN/A$1.42 per shareN/A
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$120K2,442.52N/AN/A$0.44 per share13.30
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
N/AN/AN/AN/A$1.29 per shareN/A
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
$3.34M0.96N/AN/A($5.83) per share-0.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axcella Health Inc. stock logo
AXLA
Axcella Health
-$81.19M-$19.25N/AN/AN/AN/A-259.91%N/A
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$37.94M-$1.34N/AN/AN/AN/A-629.29%-173.39%8/12/2025 (Estimated)
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
-$45.70M-$0.82N/AN/AN/AN/A-59.73%-40.05%8/5/2025 (Estimated)
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
-$22.12M-$0.72N/AN/AN/A-347.83%N/A-79.40%8/12/2025 (Estimated)

Latest CADL, ELEV, AXLA, and EVAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/27/2025Q1 2025
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
-$0.65-$0.29+$0.36-$0.29$0.06 millionN/A
5/15/2025Q1 2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
-$0.20-$0.24-$0.04-$0.24N/AN/A
5/13/2025Q1 2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$0.24$0.13+$0.37$0.13N/AN/A
4/1/2025Q4 2024
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
-$0.26-$0.07+$0.19-$0.07$1.66 million$0.12 million
3/13/2025Q4 2024
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$0.23-$0.40-$0.17-$0.40N/AN/A
3/6/2025Q4 2024
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
-$0.22-$0.18+$0.04-$0.18N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Axcella Health Inc. stock logo
AXLA
Axcella Health
N/AN/AN/AN/AN/A
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
N/AN/AN/AN/AN/A
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
N/AN/AN/AN/AN/A
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axcella Health Inc. stock logo
AXLA
Axcella Health
N/A
0.80
0.80
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
N/A
1.18
1.18
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
0.45
17.77
17.77
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
7.99
1.00
2.80

Institutional Ownership

CompanyInstitutional Ownership
Axcella Health Inc. stock logo
AXLA
Axcella Health
65.07%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
13.93%
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
83.70%
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
11.04%

Insider Ownership

CompanyInsider Ownership
Axcella Health Inc. stock logo
AXLA
Axcella Health
2.20%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
16.60%
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
8.10%
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
41.64%
CompanyEmployeesShares OutstandingFree FloatOptionable
Axcella Health Inc. stock logo
AXLA
Axcella Health
112.95 million2.88 millionOptionable
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
6050.10 million18.97 millionOptionable
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
4059.22 million54.33 millionOptionable
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
601.40 million685,000No Data

Recent News About These Companies

A Look at Evaxion Biotech's Upcoming Earnings Report
Evaxion A/S ADR
Evaxion to present at World Vaccine Congress

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Axcella Health stock logo

Axcella Health NASDAQ:AXLA

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Candel Therapeutics stock logo

Candel Therapeutics NASDAQ:CADL

$5.85 -0.09 (-1.52%)
Closing price 04:00 PM Eastern
Extended Trading
$5.79 -0.06 (-1.04%)
As of 06:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Elevation Oncology stock logo

Elevation Oncology NASDAQ:ELEV

$0.31 +0.01 (+2.03%)
Closing price 04:00 PM Eastern
Extended Trading
$0.32 +0.01 (+3.56%)
As of 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Evaxion Biotech A/S stock logo

Evaxion Biotech A/S NASDAQ:EVAX

$2.30 -0.33 (-12.55%)
Closing price 04:00 PM Eastern
Extended Trading
$2.35 +0.05 (+1.96%)
As of 06:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.